Oral administration of MRx0518 in treatment-na&#239;ve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy

MRx0518 - 4D Pharma

https://jitc.bmj.com/content/10/Suppl_2/A658

Mark Lythgoe 1; Benjamin Mullish 1; Adam Frampton 2; Paola Dama 3; Emily Pickford 1; Laura Tookman 1; Paula Cunnea 1; Christina Fotopoulou 1; Ian Jeffery 4; Gayle Fyvie 4; Alexander Stevenson 4; Jonathan Krell 1

Oct 6, 2022